Microvascular Glycocalyx Dimension Estimated by Automated SDF Imaging is not Related to Cardiovascular Disease

Microcirculation

Volumn 21, Issue 6, 2014, Pages 499-505

  Amraoui, Fouad ^a   Olde Engberink, Rik H G ^a   van Gorp, Jacqueline ^a   Ramdani, Amal ^a   Vogt, Liffert ^a   Van den Born, Bert Jan H ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Cardiovascular disease; Glycocalyx; Imaging; Microcirculation; Noninvasive

Indexed keywords

ADULT; ARTICLE; AUTOANALYSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DARK FIELD MICROSCOPE; FEMALE; GLYCOCALYX; HIGH RISK PATIENT; HUMAN; LOW RISK PATIENT; MAJOR CLINICAL STUDY; MALE; MICROCIRCULATION; MICROVASCULATURE; PRIORITY JOURNAL; SIDESTREAM DARKFIELD IMAGING; VIDEO MICROSCOPY; VIDEORECORDING; AGED; ANGIOGRAPHY; CLINICAL TRIAL; METABOLISM; MIDDLE AGED; MOUTH; PATHOLOGY; PATHOPHYSIOLOGY; VASCULARIZATION;

ADULT; AGED; ANGIOGRAPHY; CARDIOVASCULAR DISEASES; FEMALE; GLYCOCALYX; HUMANS; MALE; MICROCIRCULATION; MICROSCOPY, VIDEO; MIDDLE AGED; MOUTH FLOOR;

EID: 84905505668     PISSN: 10739688     EISSN: 15498719     Source Type: Journal    
DOI: 10.1111/micc.12125     Document Type: Article

References (32)

1. Akosah KO, Schaper A, Cogbill C, Schoenfeld P. Preventing myocardial infarction in the young adult in the first place: how do the National Cholesterol Education Panel III guidelines perform? J Am Coll Cardiol 41: 1475-1479, 2003.
2. Broekhuizen LN, Lemkes BA, Mooij HL, Meuwese MC, Verberne H, Holleman F, Schlingemann RO, Nieuwdorp M, Stroes ES, Vink H. Effect of sulodexide on endothelial glycocalyx and vascular permeability in patients with type 2 diabetes mellitus. Diabetologia 53: 2646-2655, 2010.
3. Broekhuizen LN, Mooij HL, Kastelein JJ, Stroes ES, Vink H, Nieuwdorp M. Endothelial glycocalyx as potential diagnostic and therapeutic target in cardiovascular disease. Curr Opin Lipidol 20: 57-62, 2009.
4. Canaud B, Rodriguez A, Chenine L, Morena M, Jaussent I, Leray-Moragues H, Picard A, Cristol JP. Whole-blood viscosity increases significantly in small arteries and capillaries in hemodiafiltration. Does acute hemorheological change trigger cardiovascular risk events in hemodialysis patient? Hemodial Int 14: 433-440, 2010.
5. Chappell D, Jacob M, Hofmann-Kiefer K, Bruegger D, Rehm M, Conzen P, Welsch U, Becker BF. Hydrocortisone preserves the vascular barrier by protecting the endothelial glycocalyx. Anesthesiology 107: 776-784, 2007.
6. Constantinescu A, Spaan JA, Arkenbout EK, Vink H, VanTeeffelen JW. Degradation of the endothelial glycocalyx is associated with chylomicron leakage in mouse cremaster muscle microcirculation. Thromb Haemost 105: 790-801, 2011.
7. Constantinescu AA, Vink H, Spaan JA. Elevated capillary tube hematocrit reflects degradation of endothelial cell glycocalyx by oxidized LDL. Am J Physiol Heart Circ Physiol 280: 1051-1057, 2001.
8. Constantinescu AA, Vink H, Spaan JA. Endothelial cell glycocalyx modulates immobilization of leukocytes at the endothelial surface. Arterioscler Thromb Vasc Biol 23: 1541-1547, 2003.
9. Drake-Holland AJ, Noble MI. Update on the important new drug target in cardiovascular medicine - the vascular glycocalyx. Cardiovasc Hematol Disord Drug Targets 12: 76-81, 2012.
10. Eskens BJ, Mooij HL, Cleutjens JP, Roos JM, Cobelens JE, Vink H, VanTeeffelen JW. Rapid insulin-mediated increase in microvascular glycocalyx accessibility in skeletal muscle may contribute to insulin-mediated glucose disposal in rats. PLoS ONE 8: e55399, 2013.
11. Eskens BJ, Zuurbier CJ, van HJ, Vink H, van Teeffelen JW. Effects of two weeks of metformin treatment on whole-body glycocalyx barrier properties in db/db mice. Cardiovasc Diabetol 12: 175, 2013.
12. Florian JA, Kosky JR, Ainslie K, Pang Z, Dull RO, Tarbell JM. Heparan sulfate proteoglycan is a mechanosensor on endothelial cells. Circ Res 93: 136-142, 2003.
13. KDOQI. KDOQI clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease. Am J Kidney Dis 49: S12-154, 2007.
14. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 130: 461-470, 1999.
15. Libby P. Inflammation in atherosclerosis. Nature 420: 868-874, 2002.
16. Martens RJ, Vink H, van Oostenbrugge RJ, Staals J. Sublingual microvascular glycocalyx dimensions in lacunar stroke patients. Cerebrovasc Dis 35: 451-454, 2013.
17. Mochizuki S, Vink H, Hiramatsu O, Kajita T, Shigeto F, Spaan JA, Kajiya F. Role of hyaluronic acid glycosaminoglycans in shear-induced endothelium-derived nitric oxide release. Am J Physiol Heart Circ Physiol 285: 722-726, 2003.
18. Mulders TA, Nieuwdorp M, Stroes ES, Vink H, Pinto-Sietsma SJ. Non-invasive assessment of microvascular dysfunction in families with premature coronary artery disease. Int J Cardiol 168: 5026-5028, 2013.
19. Nieuwdorp M, Meuwese MC, Mooij HL, Ince C, Broekhuizen LN, Kastelein JJ, Stroes ES, Vink H. Measuring endothelial glycocalyx dimensions in humans: a potential novel tool to monitor vascular vulnerability. J Appl Physiol 104: 845-852, 2008.
20. Nieuwdorp M, Meuwese MC, Mooij HL, van Lieshout MH, Hayden A, Levi M, Meijers JC, Ince C, Kastelein JJ, Vink H, Stroes ES. Tumor necrosis factor-alpha inhibition protects against endotoxin-induced endothelial glycocalyx perturbation. Atherosclerosis 202: 296-303, 2009.
21. Nieuwdorp M, Mooij HL, Kroon J, Atasever B, Spaan JA, Ince C, Holleman F, Diamant M, Heine RJ, Hoekstra JB, Kastelein JJ, Stroes ES, Vink H. Endothelial glycocalyx damage coincides with microalbuminuria in type 1 diabetes. Diabetes 55: 1127-1132, 2006.
22. Nieuwdorp M, van Haeften TW, Gouverneur MC, Mooij HL, van Lieshout MH, Levi M, Meijers JC, Holleman F, Hoekstra JB, Vink H, Kastelein JJ, Stroes ES. Loss of endothelial glycocalyx during acute hyperglycemia coincides with endothelial dysfunction and coagulation activation in vivo. Diabetes 55: 480-486, 2006.
23. Nora JJ, Lortscher RH, Spangler RD, Nora AH, Kimberling WJ. Genetic-epidemiologic study of early-onset ischemic heart disease. Circulation 61: 503-508, 1980.
24. Pantoni L, Garcia JH. Pathogenesis of leukoaraiosis: a review. Stroke 28: 652-659, 1997.
25. Reitsma S, Slaaf DW, Vink H, van Zandvoort MA, Oude Egbrink MG. The endothelial glycocalyx: composition, functions, and visualization. Pflugers Arch 454: 345-359, 2007.
26. Rubio-Gayosso I, Platts SH, Duling BR. Reactive oxygen species mediate modification of glycocalyx during ischemia-reperfusion injury. Am J Physiol Heart Circ Physiol 290: 2247-2256, 2006.
27. Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, McCullough PA, Kasiske BL, Kelepouris E, Klag MJ, Parfrey P, Pfeffer M, Raij L, Spinosa DJ, Wilson PW. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Hypertension 42: 1050-1065, 2003.
28. Singh A, Satchell SC, Neal CR, McKenzie EA, Tooke JE, Mathieson PW. Glomerular endothelial glycocalyx constitutes a barrier to protein permeability. J Am Soc Nephrol 18: 2885-2893, 2007.
29. VanTeeffelen JW, Brands J, Jansen C, Spaan JA, Vink H. Heparin impairs glycocalyx barrier properties and attenuates shear dependent vasodilation in mice. Hypertension 50: 261-267, 2007.
30. Vink H, Constantinescu AA, Spaan JA. Oxidized lipoproteins degrade the endothelial surface layer: implications for platelet-endothelial cell adhesion. Circulation 101: 1500-1502, 2000.
31. Vink H, Duling BR. Identification of distinct luminal domains for macromolecules, erythrocytes, and leukocytes within mammalian capillaries. Circ Res 79: 581-589, 1996.
32. Vlahu CA, Lemkes BA, Struijk DG, Koopman MG, Krediet RT, Vink H. Damage of the endothelial glycocalyx in dialysis patients. J Am Soc Nephrol 23: 1900-1908, 2012.